查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606281

支气管扩张药物市场：按药物类别、给药途径和最终用户划分 - 全球预测 2025-2030

Bronchiectasis Drugs Market by Drug Class (Anti-inflammatory Agents, Antibiotics, Bronchodilators), Route of Administration (Inhalation, Intravenous, Oral), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年支气管扩张药物市值为13.9亿美元，预计2024年将达15亿美元，复合年增长率为9.86%，预计到2030年将达27亿美元。

支气管扩张药物市场涵盖了旨在治疗支气管扩张的特定药物领域，支气管扩张是一种以肺部部分气道永久性扩大为特征的疾病。这个市场包括抗生素、祛痰剂、皮质类固醇和支气管扩张剂，这些对于治疗慢性病和预防疾病进展至关重要。呼吸系统疾病盛行率的上升、人口老化以及对支气管扩张的认识和诊断的提高推动了对这些药物的需求。其主要用途是在临床治疗中改善肺功能、减少病情恶化、控制与支气管扩张相关的细菌感染。主要终端使用者为医院、居家医疗、专科诊所和研究机构，消费族群多元化。成长要素包括药物开发的进步、医疗成本的上升以及对个人化医疗的重视。新的商机在于生物製药和基因疗法等新治疗方法的开发。公司可以透过投资研发以及与研究机构建立策略联盟来利用这些优势。然而，市场成长受到治疗成本高、新兴市场认知度低以及监管核准复杂等因素的阻碍。与学名药的竞争也是一个限制因素。创新潜力存在于开发具有更好递送机制的药物（例如吸入製剂）以及进一步研究和开发用于早期疾病检测的生物标记。市场是动态的，其特点是不断的产品创新和监管变化，要求企业保持敏捷和主动。寻求发展的公司必须跟上技术进步和新的处理技术，才能有效地利用新的市场机会。强大的供应链管理、先进的合作伙伴关係以及产品组合多元化（包括满足不同患者需求的产品）对于获得竞争优势至关重要。

主要市场统计
基准年[2023] 13.9亿美元
预计年份 [2024] 15亿美元
预测年份 [2030] 27亿美元
复合年增长率（%） 9.86%

市场动态：揭示快速发展的支气管扩张药物市场的关键市场洞察

支气管扩张药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 呼吸道感染疾病和疾病增加
    • 政府提高呼吸系统健康意识的倡议
    • 短效和长效支气管扩张药物的进入
  • 市场限制因素
    • 病原体对常见支气管扩张药物的抗药性
  • 市场机会
    • 导致吸入抗生素和先进支气管扩张剂开发的创新
    • 支气管扩张治疗药物的研发活动和临床试验
  • 市场挑战
    • 关于支气管扩张药物的安全性和有效性的监管问题

波特的五力策略工具驾驭支气管扩张药物市场

波特的五力架构是了解支气管扩张药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解支气管扩张药物市场的外部影响

外部宏观环境因素在塑造支气管扩张药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解支气管扩张治疗药物市场的竞争状况

支气管扩张治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵支气管扩张药物市场供应商的绩效评估

FPNV 定位矩阵是评估支气管扩张药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，绘製支气管扩张药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对支气管扩张药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 呼吸道感染疾病和疾病增加
      • 政府采取措施提高人们对呼吸系统健康的认识
      • 短效和长效支气管扩张药物的进入
    • 抑制因素
      • 对常见病原体抗药性的支气管扩张药物
    • 机会
      • 导致吸入抗生素和先进支气管扩张剂开发的创新
      • 支气管扩张治疗药物的研发活动和临床试验
    • 任务
      • 关于支气管扩张药物的安全性和有效性的监管问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的支气管扩张药物市场

  • 发炎剂
  • 抗生素
  • 支气管扩张剂
  • 黏液溶解药物

第七章支气管扩张药物市场：依给药途径

  • 吸入
  • 静脉
  • 口服

第八章支气管扩张药物市场：依最终用户分类

  • 诊所
  • 医院
  • 调查机构

第九章北美和南美支气管扩张药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区支气管扩张药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲支气管扩张药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AdvaCare Pharma
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group
Product Code: MRR-B1685377A3D9

The Bronchiectasis Drugs Market was valued at USD 1.39 billion in 2023, expected to reach USD 1.50 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 2.70 billion by 2030.

The bronchiectasis drugs market encompasses a specific sector of pharmaceuticals aimed at treating bronchiectasis, a condition characterized by permanent enlargement of parts of the airways in the lungs. This market's scope includes antibiotics, expectorants, corticosteroids, and bronchodilators, essential in managing chronic symptoms and preventing disease progression. The necessity for these drugs is driven by the rising prevalence of respiratory diseases, aging populations, and increasing awareness and diagnosis of bronchiectasis. Applications primarily revolve around clinical therapies to improve lung function, reduce exacerbations, and manage bacterial infections associated with the condition. Key end-users are hospitals, homecare, specialty clinics, and research institutions, highlighting a diverse consumer base. Influencing growth factors include advancements in drug development, increasing healthcare expenditure, and a stronger emphasis on personalized medicine. Emerging opportunities lie in the development of novel therapies, such as biologics and gene therapy, which promise targeted treatments with improved efficacy. Companies can capitalize on these by investing in R&D and forming strategic alliances with research institutes. However, market growth is challenged by factors such as high treatment costs, limited awareness in developing regions, and complex regulatory approvals. Competition from generic drugs also presents a limitation. Innovation potential exists in developing drugs with better delivery mechanisms, such as inhalable formulations, and conducting further research into biomarkers for early disease detection. The market is dynamic, characterized by constant product innovation and regulatory changes, requiring businesses to maintain agility and foresight. Companies seeking growth should stay abreast of technological advancements and emerging therapeutic techniques to harness new market opportunities effectively. Robust supply chain management, advanced collaborations, and diversification of portfolios to include products addressing varied patient needs will be crucial in gaining a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 1.39 billion
Estimated Year [2024] USD 1.50 billion
Forecast Year [2030] USD 2.70 billion
CAGR (%) 9.86%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of respiratory tract infections and diseases
    • Government initiatives to raise awareness about respiratory health
    • Entry of short-acting and long-acting bronchiectasis drugs
  • Market Restraints
    • Resistance of pathogenic species to common bronchiectasis drugs
  • Market Opportunities
    • Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
    • R&D activities and clinical trials to develop bronchiectasis drugs
  • Market Challenges
    • Regulatory concerns about the safety and efficacy of bronchiectasis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Bronchiectasis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchiectasis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchiectasis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchiectasis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchiectasis Drugs Market

A detailed market share analysis in the Bronchiectasis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchiectasis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchiectasis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchiectasis Drugs Market

A strategic analysis of the Bronchiectasis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiectasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchiectasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-inflammatory Agents, Antibiotics, Bronchodilators, and Mucolytics.
  • Based on Route of Administration, market is studied across Inhalation, Intravenous, and Oral.
  • Based on End-Users, market is studied across Clinic, Hospital, and Research Institute.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of respiratory tract infections and diseases
      • 5.1.1.2. Government initiatives to raise awareness about respiratory health
      • 5.1.1.3. Entry of short-acting and long-acting bronchiectasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Resistance of pathogenic species to common bronchiectasis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
      • 5.1.3.2. R&D activities and clinical trials to develop bronchiectasis drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory concerns about the safety and efficacy of bronchiectasis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchiectasis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Agents
  • 6.3. Antibiotics
  • 6.4. Bronchodilators
  • 6.5. Mucolytics

7. Bronchiectasis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral

8. Bronchiectasis Drugs Market, by End-Users

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Hospital
  • 8.4. Research Institute

9. Americas Bronchiectasis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bronchiectasis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bronchiectasis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. AstraZeneca PLC
  • 3. Boehringer Ingelheim International GmbH
  • 4. Cipla Limited
  • 5. GlaxoSmithKline PLC
  • 6. Glenmark Pharmaceuticals Limited
  • 7. Lupin Limited
  • 8. Mylan Inc. by Viatris Inc.
  • 9. Nephron Pharmaceuticals Corporation
  • 10. Novartis AG
  • 11. Perrigo Company PLC
  • 12. Pfizer Inc.
  • 13. Prasco Laboratories
  • 14. Ralington Pharma LLP
  • 15. Steris Healthcare Pvt. Ltd.
  • 16. Sun Pharmaceutical Industries Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. Zydus Group

LIST OF FIGURES

  • FIGURE 1. BRONCHIECTASIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIECTASIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIECTASIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023